Genmab A (GMAB) Retained Earnings (2023 - 2025)

Genmab A (GMAB) has disclosed Retained Earnings for 3 consecutive years, with -$181.0 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Retained Earnings rose 19.91% year-over-year to -$181.0 million, compared with a TTM value of -$181.0 million through Dec 2025, up 19.91%, and an annual FY2025 reading of -$181.0 million, up 19.91% over the prior year.
  • Retained Earnings was -$181.0 million for Q4 2025 at Genmab A, up from -$226.0 million in the prior quarter.
  • Across five years, Retained Earnings topped out at -$2.0 million in Q4 2023 and bottomed at -$226.0 million in Q4 2024.
  • Average Retained Earnings over 3 years is -$136.3 million, with a median of -$181.0 million recorded in 2025.
  • The sharpest move saw Retained Earnings plummeted 11200.0% in 2024, then rose 19.91% in 2025.
  • Year by year, Retained Earnings stood at -$2.0 million in 2023, then tumbled by 11200.0% to -$226.0 million in 2024, then rose by 19.91% to -$181.0 million in 2025.
  • Business Quant data shows Retained Earnings for GMAB at -$181.0 million in Q4 2025, -$226.0 million in Q4 2024, and -$2.0 million in Q4 2023.